GSK (NYSE:GSK) Rating Increased to Strong-Buy at StockNews.com

GSK (NYSE:GSK) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Several other brokerages have also recently issued reports on GSK. Guggenheim cut GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $34.08 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The firm’s 50-day simple moving average is $35.16 and its 200 day simple moving average is $38.68. The stock has a market cap of $70.63 billion, a price-to-earnings ratio of 22.13, a PEG ratio of 1.54 and a beta of 0.64. GSK has a fifty-two week low of $32.83 and a fifty-two week high of $45.92.

Institutional Investors Weigh In On GSK

Several large investors have recently made changes to their positions in GSK. FMR LLC grew its position in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the period. Fisher Asset Management LLC boosted its stake in GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after acquiring an additional 870,449 shares during the last quarter. Clifford Capital Partners LLC grew its position in shares of GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock valued at $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC increased its stake in shares of GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after purchasing an additional 165,556 shares during the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of GSK by 20.0% in the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after purchasing an additional 83,433 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.